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Abstract
Background: Epidural lipomatosis (EL) is an increase of adipose tissue, normally occurring in the epidural space,
sufficient to distort the thecal sac and compress neural elements. There is a lack of knowledge of risk factors,
impact on patient’s symptoms, and its possible association with epidural steroid injections.
Methods: History, physical examination, patient chart, and MRI were analyzed from 856 outpatients referred for
epidural steroid injections. Seventy patients with signs of EL on MRI comprised the study group. Thirty-four randomly
selected patients comprised the control group. The severity of EL was determined by the MRI assessment. The impact
of EL was determined by the patient’s history and physical examination. Logistic regression was used to correlate the
probability of developing EL with BMI and epidural steroid injections.
Results: EL was centered at L5 and S1 segments. The average BMI for patients with EL was significantly greater than
that of control group (36.0 ± 0.9 vs. 29.2 ± 0.9, p <0.01). The probability of developing EL with increasing BMI was linear
up to the BMI of 35 after which it plateaued. Triglycerides were significantly higher for the EL group as compared to
controls (250 ± 30 vs. 186 ± 21 mg/dL p < 0.01). The odds of having EL were 60% after two epidural steroid injections,
90% after three epidural steroid injections and approached 100% with further injections, independent of BMI. Other risk
factors considered included alcohol abuse, use of protease inhibitors, levels of stress, hypothyroidism and genetic
predisposition. However there were insufficient quantities to determine statistical significance with a degree of
confidence. The impact of EL on patient’s symptoms correlated with EL severity with Spearman correlation coefficient
of 0.73 at p < 0.01 significance level.
Conclusions: The BMI and triglycerides levels were found to be significantly elevated for the EL group, pointing
to an increased risk of EL occurrence in progressively more obese US population. The data also revealed a strong
correlation between the number of subsequent epidural steroid injections and EL occurrence calling for caution
with the use of corticosteroids.
Keywords: Epidural lipomatosis, Epidural steroid injection, Obesity, Cortisol, Sciatica
Background
Epidural lipomatosis (EL) is an increase of adipose tis-
sue, normally occurring in the epidural space, suffi-
cient to distort the thecal sac and even compress
neural elements. EL was first reported in 1975 with the
use of corticosteroids to prevent rejection of a kidney
transplant [1]. A 2005 review of the 104 cases of EL in
the literature identified four categories associated with EL:
i) exogenous steroid use, ii) obesity, iii) endogenous
steroid excess and iv) idiopathic [2]. A 2008 review of
the world literature found 111 cases of EL with 56%
secondary to corticosteroids, exogenous or endogenous
[3]. Thoracic EL was associated with corticosteroid use
and lumbar EL with obesity [3]. Tissue surgically removed
from patients with EL showed histologically normal,
un-encapsulated fat in increased amounts [2-7]. Although
the existing literature clearly points to a link between* Correspondence: rafjaimes@gmail.com1The George Washington University, 2300 I St NW Ross Hall Room 456,
Washington D.C 20037, USA
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obesity and steroid administration, there has not been a
systematic assessment of risk factors that can lead to EL,
particularly the effect of multiple steroid injections for
lower back pain. We sought to address this question using
an analysis of 856 patients referred to our clinic for lower
back pain.
Methods
IRB approval to collect data from the records was ob-
tained at Harvard Vanguard Medical Associates (HSC#
6.6.08, Coeus# 0809000134). ESI was performed in the
appropriate interspace using previously described proto-
col [8] with a standard mixture of 120 mg depomedrol
in 3 mL normal saline, both preservative free.
Review of hard copies of MR images available during
the clinical examination and assessment revealed that 52
of 856 patients had EL on the basis of deformation of
the thecal sac and/or the nerve sheath by lipoid on the
T1 films (Figures 1 and 2A). Data was analyzed in a non-
clinical setting after clinical treatment ended. To generate
a subpopulation of internal controls without EL, drawn
from the same clinical cohort, a convenience sample based
upon serial selection of one case from each dozen seen
serially was employed. Eighteen of these 52 patients from
the remaining 804, contingent on the availability of a
complete record, were found to have mild EL. These
eighteen patients were combined with the original 52
patients to form patients with EL (70 patients). The
remaining 34 patients with no signs of EL formed the
non-EL control group. A large number of EL patients
vs. control group allowed us to further subdivide the
EL group into different EL severity categories. The control
group with greater than 30 samples provided enough
statistical power to show significant comparisons between
groups.
The following data were obtained from records: date and
number of previous ESIs, age, sex, BMI range, presence
of diabetes, HA1C, mean glucose, random glucose, tri-
glycerides, cholesterol, LDL, HDL, CPK, SGPT, SGOT,
ALK- PHOS, uric acid and creatinine.
The severity of EL was graded by visually assessing the
degree of compression and distortion of the thecal sac
on all T1 images. The ratio of cross sectional area of epi-
dural fat to that of the dural sac was used as a guide. In
the L5 and S1 area, if epidural fat occupied a cross-
sectional area up to that of the dural sac, it was considered
mild (Figure 2A); up to twice was moderate (Figure 2B);
and greater than twice was severe (Figure 2C). However,
in the more cephalad segments, the neural elements oc-
cupy a larger section of the spinal canal thus; a smaller
area of epidural fat can produce severe compression as
in the upper lumbar spine (Figure 2D). The grading was
done on a visual basis, simplified for use in the clinic as
none, minimal, moderate and severe EL. To confirm vis-
ual grading scheme, linear measurements of epidural fat
on MRI were made in both EL and non-EL control
groups using an electronic ruler on Fuji PACS system:
the epidural fat, anterior and posterior to the thecal sac
was measured in the sagittal image tangent to the superior
cortex of S1; the posterior subcutaneous fat was measured
horizontal to the L4/L5 interspace (Figure 3A). The corre-
sponding image from the axial plane showing measure-
ment discrepancies is shown in Figure 3B.
All statistical analysis was performed in SAS 9.3. BMI,
triglycerides, cholesterol, and fat from sagittal measure-
ments (total epidural and posterior subcutaneous) were
compared with Wilcoxon-Mann–Whitney (WMW) and/
or T-test as noted. Statistical significance was defined at
p-values of less than 0.01.
A Spearman correlation test was performed between
values of BMI and the EL severity, BMI and the EL impact
on patient’s symptoms, and the EL severity vs. the EL
symptoms. Equality of gender was shown using a binomial
exact test. The number of epidural steroid injections (ESI)
or BMI vs. probability to develop EL was computed by





¼ β0 þ β1 Varð Þ ð1Þ
Where β0 and β1 are the solved coefficients, Var is the
number of ESI given or BMI, and pi is the probability of
acquiring EL. The correlation was considered to be signifi-
cant for variables with a p-value of less than 0.01. Logistic
regression was calculated separately for BMI and ESI to
ensure independence.
Figure 1 Comparison of the sacral area on T1 and T2 sagittal
images. (A) The T1 on the left shows the thecal sac is partially
obscured by EL. (B) The T2 sagittal MR image on the right shows
a clear outline of the thecal sac ending at mid S2.




After above mentioned selection from an original pool
of 856 patients, there were a total of 104 patients ana-
lyzed. This included 70 patients with EL and 34 with-
out EL. There were 43 men and 61 women in the
study. A binomial test of these two groups resulted in a
p < 0.05, confirming that the numbers of men and
women in both groups were statistically equal. The
average age of the patients was 61.8 ± 2.8 years. Those
with EL had an average age of 61.7 and those without,
61.8.
Identification of EL
T1 weighted MR images were used for identification of
EL as displayed in the sacral area on the sagittal image
(Figure 1A). As shown in Figure 1B, T2 weighted images
may not allow enough contrast between fluid and fat.
Out of 70 EL patients, 46 were classified as mild.
Figure 2A exemplifies mild EL: enhanced visibility of
the L5 roots and mildly indented thecal sac. Sixteen
patients were classified with moderate severity, as ex-
emplified in Figure 2B: enhanced L5 roots and cross
sectional area of epidural fat greater than that of the
thecal sac. Figure 2C is an image at L5/S1 and is indi-
cative of severe EL: the thecal sac is compressed to
form a Y-shape. There were eight patients with the
classification of severe EL. Figure 2D is an image taken
at the L4 level and illustrates the case where although
the thecal sac and epidural fat are equal, the neural
elements are compressed significantly thus considered
severe.
Figure 2 Severity of EL can be determined from physical features. (A) Axial image through the body of L5 with early EL. The L5 nerve roots
are visible from thecal sac to Lateral Recesses. Epidural Lipomatosis (EL) enhances the visibility of the L5 roots. The arrow points to the
indentation of the thecal sac. (B) Epidural fat tethering dural sac producing stellate appearance and moderate EL. (C) Axial MR image through
the body of S1 with severe EL. The arrow points to the thecal sac in the shape of a Y (pathognomonic for severe EL). The buttock muscles are
infiltrated with fat and the overlying subcutaneous tissue is excessive. (D) Axial MR image through the body of L4 with EL, compressing the
roots and thecal sac. Since the neural elements normally occupy a larger area of the spinal canal at L4 than L5/S1, the compression by EL is
considered severe.
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A misdiagnosis that may occur is that arachnoiditis is
confused with EL. The sagittal MR image may show
severe EL and an irregularly compressed dural sac confus-
able with arachnoiditis (Figure 4). Using the T1 image,
enhanced contrast will help the clinician to distinguish the
two.
Linear image measurements of epidural and of
subcutaneous fat
The anterior and posterior epidural, and posterior sub-
cutaneous fat measurements were made in both EL and
non-EL control groups using a Fuji PACS system in the
sagittal (Figure 3A) and axial planes (Figure 3B). The
measurements of fat varied slightly between the
orientations. Measurements in the sagittal plane were
more consistently replicable than in the axial plane. Sa-
gittal epidural fat measurements were combined and
reported as total epidural fat. The total epidural fat for
patients with EL was significantly greater than the total
for non-EL control group as determined by WMW test
(7.2 ± 0.4 mm vs. 5.0 ± 0.4 mm, p < 0.01). Qualitative
visual analysis of lipomatosis grades revealed a nearly
linear correlation with total epidural fat measurements
(Figure 5A). The comparison of total epidural fat of
males and females showed no difference within their
respective groups. However, females had significantly
more posterior subcutaneous fat than males within their
respective groups, p < 0.01. Posterior subcutaneous fat was
Figure 3 Comparison of sagittal and axial images. (A) Sagittal T1 showing epidural fat measurements along a line tangent to the superior
cortex of S1, anterior (7.8 mm) and posterior (3.9 mm). The thickness of posterior subcutaneous fat was measured horizontal to the L4/L5
interspace, line labeled 32.7 mm. (B) Axial image showing measurement discrepancy: anterior epidural fat is 7.2 mm, posterior epidural fat is 3.3
mm, and posterior subcutaneous fat is at least 36.7 mm.
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also significantly greater in patients with EL than non-EL
(37.5 ± 2.6 mm vs. 27.9 ± 2.0 mm, p < 0.01).
Increased body mass index and triglycerides are
associated with epidural lipomatosis (EL)
The average BMI for all patients in the study was
33.7 ± 0.7 (obese). The average BMI for men was
33.4 ± 1.1 and 33.6 ± 0.9 for women. Both T-test and
WMW test had p-values of 0.8 and 0.15, respectively, sug-
gesting no difference in BMI based on gender.
The average BMI for patients with no EL was 29.2 ± 0.9
and those with EL was 36.0 ± 0.9. A weighted T-test and
WMW test had p < 0.01, suggesting there is a difference
in BMI between the two groups. An ANOVA with Tukey
post-hoc test on BMI between different grades of lipoma-
tosis revealed significant differences for all grades of EL
severity when compared to the control group (p < 0.01),
but no difference comparing the different grades of
lipomatosis (Figure 5B). BMI was found to be statisti-
cally significant for the logistic regression model with a
p < 0.01. The probability of developing EL was linear
with increasing likelihood as BMI increases, until a BMI
of 35 after which point it plateaus (Figure 6A).
Those with EL had an average triglycerides value
of 250 ± 30 and those without EL had an average of
186 ± 21 mg/dL. To account for the fact that triglycerides
values were positively skewed in both groups, a WMW
test was used. Triglycerides in the EL group were sig-
nificantly elevated compared to the control group with
p < 0.01. Triglycerides do not independently determine
the probability of developing EL with a p > 0.01 in a logis-
tic regression model.
Severity of lipomatosis on patient’s symptoms
The chief complaints, causes, and associated complaints
were determined from history and physical examination as
specified in Table 1. Twenty-eight (40%) EL patients com-
plained of pain on walking relieved in a few minutes with
sitting (neurogenic claudication). Forty-two (60%) com-
plained of sciatica. EL was the primary cause of sciatica in 9
of 42 (21%) but may be contributory in other patients. The
impact of EL on patient’s symptom impact was then graded
as none, minimal, moderate and high. The Spearman chi-
square p-value for EL severity vs. impact was <0.0001
showing that there is strong association between EL sever-
ity and symptomatic impact (Table 2). The early stages of
the development of EL had low or no symptomatic impact.
Epidural steroid injections, stress, & alcohol consumption
The number of ESI deliveries was significant in an inde-
pendent logistic regression model with a p < 0.01. Absence
of ESI deliveries or one ESI delivery did not increase the
patient’s odds of developing EL. After two ESI the odds of
developing EL was 66%. After three ESI, the odds were
98%. Four or more ESI increased the odds approaching
100%.
The average number of ESI delivered in the patients
with no EL was 1.0 ± 0.0, and there were no patients
who received more than one. The average number of
ESI delivered was 1.8 ± 1.5 to the EL group. There were
two patients in the EL group who did not receive any
ESI. Their BMI were 40 and 42.
It was noted in the charts of ten patients in the EL
group who self-reported stress and eight who self-reported
alcohol consumption. No patients in the control group
reported stress or alcohol consumption.
Discussion
Definition, location, severity, impact
The definition of EL presently available, “an excessive
accumulation of normally occurring fat in the epidural
space” [2-7,9-11], does not provide a definitive bound-
ary between the normal and excessive amount of fat in
the epidural space thus we added visible deformation of
the thecal sac/neural elements to provide a more definitive
end point.
Our observation that EL is centered on L5 to S1 ex-
tending to include some cephalad and caudad segments,
Figure 7, is consistent with the findings of Borre et al. [4].
Severity was correlated with impact. Pinkhardt et al.,
found a “very insecure association (of EL) with clinical
symptoms” [11]. They made measurements in L5/S1 axial
images according to Borre [4] retrospectively, excluding
patients with deformities whereas our study included all
Figure 4 T1 sagittal image confusable with arachnoiditis.
The arrow at S1 points to excessive anterior fat and a
compressed thecal sac.
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Figure 5 Grade of lipomatosis severity increases with epidural fat and BMI. (A) Holistic grading approach of EL scales with quantitative
total epidural fat measurements. (B) BMI was statistically different between control and EL group, but not different between grades of EL.















































Figure 6 Probabilities of developing EL computed by logistic regression. (A) Probability computed with BMI as the variable. (B) Probability
computed with number of prior epidural steroid injections as the variable.
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sagittal and axial T1 MR images. The MRI findings must
be put in the context of the history and physical exam.
The mean BMI for the control group was under 30,
but approximately 34 for EL patients indicating that
there is step response beyond the threshold of obesity
(Figure 5B). With a BMI of 28, the probability of EL is
only 50% which hints there are other contributing fac-
tors. Other causative factors, including, but not limited
to ESI and elevated triglycerides, will significantly con-
tribute to the probability of developing EL up to a BMI
of 35. The probability of developing EL is linear with
increasing BMI until a value of 35, at which point the
probability curve begins to plateau (Figure 6A). Once
BMI is greater than 35, the other causative factors have
less of a contribution toward the probability of devel-
oping EL, but may contribute to the grade of EL sever-
ity. The grade of EL severity is not correlated with BMI
(Figure 5B).
The causes of epidural lipomatosis
The probability of developing EL is linear with increasing
BMI between 28 and 35. BMI of 28 acts as a threshold
for developing EL and at a BMI 35 its influence begins
to wane. There are other factors involved which will be
discussed later. Obesity, BMI over 30, is an imputed
cause of EL [2-4,10,12,13] which provides a milieu for
the enzyme, 11β-HSD-1 to convert corticosteroids to
cortisol [14], Diet induced obesity leads to an increase
in 11β-HSD-1 which increases cortisol by the local
conversion of corticosteroids to the biologically active
cortisol [14]. Corticosteroids also, an imputed cause of
EL [2-4,6,15-19], fit into the schema by providing the
substrate for the formation of cortisol.
Study of the physiology of cellular liporegulation in
rodents sheds some light on the role of Leptin in human
metabolism of fat [14]. Leptin is required for normal
liporegulation in tissues just as insulin is required for
normal glucoregulation. In over-nutrition, leptin allows
extra fat to be deposited in body fat without metabolic
injury to non-adipose tissues. An increase in cortisol
leads to leptin resistance; exacerbated by glucocorticoid
administration [20] and ameliorated by adrenalectomy
[21]. If leptin is overwhelmed, then deposition of fat may
take place in the liver, heart, muscles and pancreas caus-
ing lipotoxicity or lipoapoptosis [14]. The liver has a
margin of safety by exporting triglycerides in the form of
very low density lipoproteins (VLDL); the muscle can
metabolize triglycerides as a result of exercise, but the
pancreas has neither of these options [14].
A phase IIB study in patients with Type 2 diabetes
given an antagonist to the enzyme 11β-HSD-1 responsible
for conversion of corticosteroids to cortisol showed in-
creased insulin sensitivity and improvement in: glycemic
control, total cholesterol, LDL-cholesterol and triglycer-
ides [22]. Studies are needed to show if 11β-HSD-1 and
cortisol lead to EL.
Hypertriglyceridemia may develop due to overeating
and/or under-exercising [23,24]. Obesogens can alter
regulation of energy balance to favor weight gain and
obesity [25]. Also, an increase in adipose tissue cortisol
can lead to lipolysis with increased triglycerides [26].
EL and ESI
Reports have related the development of EL to the
administration of epidural steroid injections [27-30]. Four
patients were refused ESI because the EL was severe and
structural defects were minimal. Although the probability
of developing EL is over 90% after four ESI, the severity
and thus symptomatic impact of EL may not be significant.
The incidence of EL was not assessed in this study. The
corticosteroid from the ESI provides the substrate for the
formation of cortisol.
Table 1 Categories of Chief Complaint
Chief complaint Primary causes EL group (n = 70) Associated complaints
Neurogenic Claudication (n=28)
Triad1 14 No Sciatica
Foraminal Stenosis 9 Sciatica
DJD2 5 Facetal Pain
Sciatica (n=42)
HNP3 25 Radicular pain, sensory and/or motor deficit
EL4 9
Foraminal Stenosis 8
1Disc bulge, thickened ligamentum flavum, facet hypertrophy (spinal stenosis). 2Degenerative joint disease (spondylolisthesis and/or facet arthropathy). 3Herniated
nucleus pulposis. 4Epidural lipomatosis.
Table 2 Severity of EL and its relationship to gradation of
impact
Impact None Minimal Moderate Severe
EL severity
Mild 32 13 1 0
Moderate 0 3 11 2
High 0 2 3 3
The Spearman correlation severity vs. impact (R2 = 0.73, p < 0.0001).
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The response to stress, as formulated by Selye [31],
causes the release of corticotrophin by the pituitary; corti-
sol, epinephrine and other hormones by the adrenal gland.
The cortisol, thus produced, augments the cortisol from
the adipose tissue, ultimately promoting the metabolic
syndrome [14,15,20,32-34]. The case-controlled study by
Brunner et al. provides evidence that chronic stress may
be a cause of metabolic syndrome [35]. Only our patients
that developed EL reported stress.
Studies of alcohol abuse on metabolic syndrome are co-
gent since EL and metabolic syndrome share many com-
ponents. Some studies have shown a beneficial effect of
alcohol on the development of metabolic syndrome. How-
ever Baik found an increased risk of metabolic syndrome
was associated with “obese, heavy liquor drinking persons”
[36]. Alcohol feeding of patients on a metabolic ward in-
creased plasma triglycerides, the obese responding with a
45% increase in the production of VLDL-TG [37]. Thus,
the caveat: mild or moderate alcohol consumption may be
protective, but only in persons who are not obese. Only
patients in the EL group reported alcohol consumption.
Conclusion
The development of EL is multi-factorial, the risk factors
being intertwined and additive. Obesity is the principal
risk factor associated with lumbar epidural lipomatosis.
Lumbar EL may worsen after the first ESI injection. The
symptomatic impact of EL is correlated with its severity.
EL may be the principal cause of sciatica and secondary
cause of neurogenic claudication. The present trend in
obesity portends a marked increase in epidural lipomatosis
[38]. Weight loss programs have reversed EL and its
symptoms, including neurogenic claudication and cauda
equina compression [39-43]. The density of cases is suffi-
cient to formulate controlled studies.
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